In this review:
This review discusses the evidence on secukinumab (Cosentyx®), a high-affinity, human, monoclonal antibody, for the management of moderate-to-severe plaque psoriasis, focusing on the outcomes from the phase 3 studies in patients with plaque psoriasis (ERASURE, FIXTURE, FEATURE, and JUNCTURE), as well as data from long-term follow-up of up to 5 years. Secukinumab is funded as a first- and second-line treatment for severe chronic plaque psoriasis on Special Authority application. This review is sponsored by an educational grant from Novartis (NZ) Ltd.
Please login below to download this issue (PDF)